Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its latest quarterly report later this week. Analysts are predicting strong performance driven by the robust sales of Lilly's blockbuster drugs, particularly the diabetes franchise. However, there are also concerns about potential challenges fro